Skip to content
Screener

R&D at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$91.26M-55.4%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$33.81M+117%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$100.87M-7.4%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$14.38M-6.5%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$9.84M+145%
Regenxbio logo
RegenxbioRGNX
$56.09M-5.7%

Other financials

Income statement

See full
Revenue$5.8M+11.0%
Gross profit$5.5M+19.2%
Operating income-$52.2M-19.0%
Net income-$81.1M-115%
EPS (diluted)-$1.22-76.8%

Balance sheet

See full
Cash & equivalents$413.0M+62.8%
Total debt$62.8M-5.8%
Total equity$324.1M+8,195%
Total assets$985.1M+68.4%

Cash flow

See full
Operating cash flow-$28.6M+28.4%
CapEx$472.0K+81.5%
Free cash flow-$29.0M+27.7%

Valuation

See full
Market cap$3.15B+325%
Enterprise value$2.8B+406%
P/S168.5×+117×

Profitability

See full
Gross margin92.5%+4.6pp
Operating margin-1,071.5%-90.6pp
Net margin-1,350.7%-35.3pp
FCF margin-864.7%-194pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.2×
Current ratio10×0.0×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: uniQure’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 7:17 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087815
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Total revenues5,8415,2629,4036,829
Operating expenses:
Cost of license revenues(350)(656)(569)(853)
Research and development expenses(33,964)(35,383)(63,140)(71,523)
Selling, general and administrative expenses(17,367)(13,500)(37,435)(24,408)
Total operating expenses(51,681)(49,539)(101,144)(96,784)
Other income1,5982,5973,23010,903
Other expense(7,961)(2,185)(9,412)(4,144)

Item 1.Financial Statements

FAQ

What is uniQure's R&D?
uniQure (QURE) reported R&D of $33.96M in Q2 2026.
How has uniQure's R&D changed year-over-year?
uniQure's R&D decreased by 4.0% year-over-year, from $35.38M to $33.96M.
What is the long-term trend for uniQure's R&D?
Over 4 years (2021 to 2025), uniQure's R&D has grown at a -0.6% compound annual growth rate (CAGR), from $144.17M to $140.67M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Ask your AI about uniQure's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude